Emerging drugs for primary progressive multiple sclerosis

The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice

(2017) Chika Higashi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Neuronal effects of thyroid hormone metabolites

(2017) Eva K. Wirth et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Imaging outcome measures for progressive multiple sclerosis trials

(2017) Marcello Moccia et al.   Multiple Sclerosis Journal

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imaging outcome measures for progressive multiple sclerosis trials

(2017) Marcello Moccia et al.   Multiple Sclerosis Journal

MicroRNAs associated with the pathogenesis of multiple sclerosis

(2016) Qingrong Huang et al.   JOURNAL OF NEUROIMMUNOLOGY

Primary progressive multiple sclerosis—why we are failing

(2016) Benjamin M Segal et al.   LANCET

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyelination in mice

(2016) Adib Zendedel et al.   METABOLIC BRAIN DISEASE

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

The effect of triiodothyronine on maturation and differentiation of oligodendrocyte progenitor cells during remyelination following induced demyelination in male albino rat

(2016) H. El-Tahry et al.   TISSUE & CELL

Laquinimod in the treatment of multiple sclerosis: a review of the data so far

(2016) Jan Thöne et al.   Drug Design Development and Therapy

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis

(2016) Ludwig Kappos et al.   JAMA Neurology

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Dimethyl fumarate may still have a role in progressive multiple sclerosis

(2016) Domenico Plantone et al.   Therapeutic Advances in Neurological Disorders

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

(2016) Mika Komori et al.   Annals of Clinical and Translational Neurology

Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis

(2015) Mika Komori et al.   ANNALS OF NEUROLOGY

Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway

(2015) Qin Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis

(2015) Steffi Grey (née Cotte) et al.   JOURNAL OF NEUROIMMUNOLOGY

Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis

(2015) Marcus W. Koch et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

(2015) Daniel Ontaneda et al.   LANCET NEUROLOGY

Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis

(2015) Martina Absinta et al.   NEUROLOGY

Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis

(2015) Daniel M. Harrison et al.   JAMA Neurology

High doses of biotin in chronic progressive multiple sclerosis: A pilot study

(2015) Frédéric Sedel et al.   Multiple Sclerosis and Related Disorders

Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials

(2014) Mickael Bonnan et al.   CURRENT DRUG TARGETS

Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?

(2014) Sausan Jaber et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Lithium Prevents and Ameliorates Experimental Autoimmune Encephalomyelitis

(2014) P. De Sarno et al.   JOURNAL OF IMMUNOLOGY

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study

(2014) Katrin Strassburger-Krogias et al.   Therapeutic Advances in Neurological Disorders

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation

(2014) Manoj Kumar Mishra et al.   Annals of Clinical and Translational Neurology

Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls

(2013) Sergio E. Baranzini et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis

(2013) Valérie Jolivel et al.   BRAIN

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride

(2013) Tarunya Arun et al.   BRAIN

Novel immunoregulatory properties of EGCG on reducing inflammation in EAE

(2013) Hong Nie   Frontiers in Bioscience-Landmark

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions

(2013) Corinne Brana et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions

(2013) Veela Mehta et al.   PLoS One

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

(2013) Sharmilee Gnanapavan et al.   PLoS One

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

(2012) Patrick Vermersch et al.   BMC Neurology

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis

(2012) Sung R. Choi et al.   BRAIN

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury

(2012) Marie T. Fischer et al.   BRAIN

The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration

(2012) Jason C. Dugas et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS

(2012) Robert J Fox et al.   Multiple Sclerosis Journal

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis

(2012) B. G. Arnason et al.   Multiple Sclerosis Journal

Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling

(2012) Amber L. Rowse et al.   PLoS One

Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor

(2011) Jan Thöne et al.   AMERICAN JOURNAL OF PATHOLOGY

Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla

(2011) F. Bagnato et al.   BRAIN

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model

(2011) Sandra Vergo et al.   BRAIN

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

(2011) Owain W. Howell et al.   BRAIN

The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

(2011) B. Soliven et al.   NEUROLOGY

Fluoxetine protects neurons against microglial activation-mediated neurotoxicity

(2011) Feng Zhang et al.   PARKINSONISM & RELATED DISORDERS

Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords

(2010) Géraldine Androdias et al.   ANNALS OF NEUROLOGY

Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients

(2010) Ranjan Dutta et al.   ANNALS OF NEUROLOGY

Demyelination versus remyelination in progressive multiple sclerosis

(2010) Stephan Bramow et al.   BRAIN

Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis

(2010) B.C. Cheah et al.   CURRENT MEDICINAL CHEMISTRY

Characterization of brain lesions in a mouse model of progressive multiple sclerosis

(2010) H. Levy et al.   EXPERIMENTAL NEUROLOGY

Demyelination Increases Axonal Stationary Mitochondrial Size and the Speed of Axonal Mitochondrial Transport

(2010) S. Kiryu-Seo et al.   JOURNAL OF NEUROSCIENCE

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Human Mast Cells Stimulate Activated T Cells

(2009) Theoharis C. Theoharides et al.   Annals of the New York Academy of Sciences

Mitochondrial changes within axons in multiple sclerosis

(2009) D. J. Mahad et al.   BRAIN

Demyelination, Inflammation, and Neurodegeneration in Multiple Sclerosis Deep Gray Matter

(2009) Marco Vercellino et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Glatiramer acetate treatment in PPMS: Why males appear to respond favorably

(2009) Jerry S. Wolinsky et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

How mitochondria produce reactive oxygen species

(2008) Michael P. Murphy   BIOCHEMICAL JOURNAL

Remyelination in the CNS: from biology to therapy

(2008) Robin J. M. Franklin et al.   NATURE REVIEWS NEUROSCIENCE

Elevated myeloperoxidase activity in white matter in multiple sclerosis

(2008) Elizabeth Gray et al.   NEUROSCIENCE LETTERS

Neuroprotective actions of melanocortins: a therapeutic opportunity

(2008) Anna Catania   TRENDS IN NEUROSCIENCES

Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis

(2008) Claudia Bartels et al.   Therapeutic Advances in Neurological Disorders

Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS

(2008) Sonemany Salinthone et al.   Endocrine Metabolic & Immune Disorders-Drug Targets